

SUMMARY	4
GLAUCOMA: A LEADING CAUSE OF BLINDNESS	6
WHAT ARE CONNEXINS?	7
THE BYSTANDER EFFECT	7
RETINAL CONNEXINS.....	9
CONNEXIN INHIBITION PROTECTS RETINAS	10
CAN WE RESTORE VISION?	12
OUR APPROACH: CONNEXIN 36 BLOCKADE.....	15
TREATMENT PARADIGMS & COMMERCIAL POTENTIALS	16
GLAUCOMA TREATMENT PARADIGM.....	16
<i>Glaucoma Commercial Potential</i>	18
RETINOPATHIES – TREATMENT PARADIGMS & COMMERCIAL POTENTIAL	20
CORNEAL DISEASES – TREATMENT PARADIGMS & COMMERCIAL POTENTIAL.....	21
<i>Connexin 43 Inhibition for Retinopathy?</i>	22
COMPETITION – CONNEXIN INHIBITORS	23
COMPETITION – OTHER RETINAL NEUROPROTECTANTS	24
OUR PROPRIETARY CONNEXIN INHIBITORS	25
RESEARCH PLAN	26
IN SILICO / AI CHEMISTRY.....	27
HIGH-THROUGHPUT CELL-CELL ASSAYS	28
CHEMISTRY: DESIGN & SYNTHESIS OF CONNEXIN INHIBITORS.....	30
<i>Novel Compounds – Synthesis and Optimization</i>	30
<i>Secondary Screen – Glaucomatous Zebrafish Model</i>	30
ANIMAL STUDIES - GLAUCOMA.....	33
CONNEXIN 45 & 43 INHIBITORS – OPPORTUNITIES AND RESEARCH PLAN	33
RESEARCH PLAN – MILESTONES & ESTIMATED TIMELINES.....	35
IMPACT FROM COVID-19	36
BUDGET	36
COMMENTS ON SPENDING PLAN	37
WHAT HAPPENS NEXT?	39
SERIES A PLANS AND ACTIVITIES.....	39
OPHTHALMOLOGY PARTNERSHIPS & RELATED TRANSACTIONS	41
FUTURE STRATEGIC OPTIONS.....	43
OPERATING PLAN	45
INTELLECTUAL PROPERTY STRATEGY	45
MANAGEMENT TEAM	46
KEY PARTNERS & CONSULTANTS	48
CONCLUSION	50
FREQUENTLY ASKED QUESTIONS	50
<i>Does MFA work Weeks after Inducing Glaucoma?</i>	50

<i>How will your drug be delivered to the back of the eye?</i>	51
APPENDIX A – SCIENTIFIC DISCUSSION	53
<i>Gap Junctions and the Bystander Effect</i>	53
<i>Connexin 36 & 45 Blockade</i>	54
APPENDIX B – GLAUCOMA PIPELINE ANALYSIS	59
GLAUCOMA PIPELINE – PHASE II-III.....	59
GLAUCOMA PIPELINE – PRECLINICAL & PHASE I.....	60
APPENDIX C – CUSTOMER PIPELINE / GO TO MARKET	61
APPENDIX D – APPROVED INTRAVITREAL PRODUCTS	62
LITERATURE CITED	63